Table 5.

Clinical characteristics of patients with other conditions, VFI and MD follow-up, and progression rate.

Case	Disease	Follow-Up Months	Eye	Initial VFI (%)	Final VFI (%)	Initial MD (dB)	Final MD (dB)	VFI Progression Rate (%/year) 1
OC01	Optic neuritis	92 2	Right	87	97	−9.54	−2.61	+0.9 ± 0.5
			Left	71	94	−9.89	−3.19	−2.4 ± 0.6
OC02	Optic neuritis causing optic nerve atrophy	97 2	Right	99	98	−1.44	−2.22	−0.4 ± 0.4
			Left	70	91	−11.12	−7.06	+0.8 ± 3.5
OC03	Bilateral optic neuritis	16 2	Right	48	92	−20.89	−5.65	+24.2 ± 28.2
			Left	22	93	−27.32	−3.94	+61.7 ± 32.9
OC04	Optic nerve atrophy (post-meningitis)	63 2	Right	0	11	−31.02	−25.79	+76.2 ± 12.3
			Left	2	91	−30.22	−2.4	+257.0 ± 42.30
OC05	Optic nerve atrophy (intracranial hypertension)	110 2	Right	89	85	−0.87	−7.12	+1.3 ± 3.8
			Left	89	88	1.15	−6.72	+0.6 ± 2.4
OC06	Optic nerve atrophy (drug toxicity, etambutol)	22 2	Right	86	99	−4.58	−0.28	+4.2 ± 2.4
			Left	87	99	−5.67	−0.1	+7.1 ± 3.0
OC07	Neuroretinitis	26 2	Right	70	88	−11.47	−2.31	+6.8 ± 5.4
			Left	100	100	4.06	4.18	+0.1 ± 0.4
OC08	Tapetoretinal dystrophy (with superior hemianopia)	34 2	Right	31	40	−26.17	−20.8	+2.2 ± 2.9
			Left	22	48	−27.64	−18.42	+2.5 ± 3.9
OC09	Retinitis pigmentosa	53 3	Right	12	49	−27.92	−19.46	+0.0 ± 3.7
			Left	19	49	−26.88	−19.85	+0.4 ± 2.7
OC10	Unknown	14 2	Right	5	80	−28.75	−7.54	+15.5 ± 4.4
			Left	11	88	−27.76	−8.5	+10.0 ± 4.9
OC11	Unknown (optic nerve injury)	68 4	Right	95	98	−5.13	−1.9	+4.1 ± 24.6
			Left	90	99	−6.4	−0.34	+4.6 ± 22.0
OC12	Cone dystrophy	103 5	Right	66	70	−6.99	−9.96	+0.1 ± 1.7
			Left	71	70	−7.39	−10.0	−0.6 ± 1.1
OC13	Retinal vascular occlusion	89 6	Right	99	99	−0.22	−0.51	+0.6 ± 1.7
			Left	31	58	−24.44	−17.84	+5.2 ± 2.9

¹ 95% confidence level. ² Initiation of CoQ10 treatment in month 0. ³ Initiation of CoQ10 treatment in month 47. ⁴ Initiation of CoQ10 treatment in month 40. ⁵ Initiation of CoQ10 treatment in month 93. ⁶ Initiation of CoQ10 treatment in month 57.